Glaukos announces positive three-year Epioxa results demonstrating durable clinical outcomes in keratoconus
GKOS•Glaukos said three-year follow-up showed durable efficacy and favorable safety for Epioxa, with no serious adverse events or discontinuations reported.
1. Three-year follow-up
Glaukos said three-year follow-up showed durable efficacy and favorable safety for Epioxa in keratoconus, with no serious adverse events or discontinuations reported.
